How to Get Lantus (Insulin Glargine) in Washington State

What Is Lantus and Why Washington Patients Need It

Lantus is the brand name for insulin glargine 100 units/mL, a long-acting basal insulin analog that Sanofi manufactures and the FDA approved in April 2000 for subcutaneous injection once daily in adults and children aged 6 and older with type 1 or type 2 diabetes [1]. The drug provides a relatively flat, peakless 24-hour insulin profile by forming microprecipitates at the subcutaneous injection site after the acidic (pH 4) formulation neutralizes in tissue [2].

The American Diabetes Association 2024 Standards of Care classify insulin glargine as a preferred basal insulin option for patients requiring insulin therapy, noting that long-acting analogs produce fewer nocturnal hypoglycemia events than NPH insulin [3]. Washington State had an estimated 580,000 adults living with diagnosed diabetes as of the 2022 CDC surveillance report, meaning access pathways for basal insulin remain a practical priority for a large patient population [4].

The ORIGIN trial (N=12,537, NEJM 2012) is the landmark cardiovascular safety study for insulin glargine. Investigators randomized adults with dysglycemia to insulin glargine or standard care and observed no significant difference in cardiovascular outcomes over a median of 6.2 years, confirming the drug's long-term safety profile [5]. That trial also documented a median HbA1c of 5.9% in the glargine arm versus 6.2% in standard care, a clinically meaningful glycemic difference achieved without increased major cardiovascular events.

Who Can Prescribe Lantus in Washington State

Any licensed prescriber with Washington State DEA and controlled-substance authority can write a Lantus prescription, although insulin is not a controlled substance and therefore does not require DEA scheduling [6]. The following credential types are legally authorized to prescribe insulin glargine in Washington:

• Medical doctors (MD) and doctors of osteopathic medicine (DO) under RCW 18.71
• Advanced registered nurse practitioners (ARNP) operating under full practice authority granted by Washington State in 2023 [7]
• Physician assistants (PA-C) under RCW 18.71A with prescriptive authority delegation or autonomous practice as permitted under the 2023 PA Practice Act amendment

Washington ARNPs gained full independent practice authority effective July 2023, meaning they no longer require a collaborative agreement with a physician to prescribe insulin or any other non-controlled medication. This change substantially expanded the number of clinicians who can initiate Lantus therapy without requiring a specialist referral.

Certified diabetes care and education specialists (CDCES) are not independent prescribers but often co-manage insulin titration protocols under a supervising prescriber's standing orders. Patients working with a CDCES in Washington should confirm whether their educator operates under such an order set so titration adjustments can occur between physician visits [8].

Getting a Lantus Prescription Through Telehealth in Washington

Washington law allows telehealth prescribing for insulin glargine without a prior in-person visit, provided the clinician conducts a synchronous audio-video evaluation that meets the standard of care [9]. The Washington State Department of Health confirmed in 2020 guidance that prescribing for chronic conditions including diabetes is appropriate via telehealth when the clinician can adequately assess the patient and review records [10].

A typical telehealth visit for Lantus initiation in Washington runs 20 to 30 minutes and covers current glucose logs, prior insulin history, renal function results, hypoglycemia risk, and injection technique review. The prescriber then sends the prescription electronically to the patient's preferred Washington pharmacy.

HealthRX Telehealth Initiation Framework for Lantus in Washington

1. Schedule a synchronous video visit with a Washington-licensed MD, DO, ARNP, or PA-C.
2. Upload recent lab work (HbA1c, BMP, eGFR) to the patient portal at least 24 hours before the visit.
3. During the visit, the prescriber calculates the starting dose (typically 10 units or 0.1, 0.2 units/kg/day, whichever is lower, per ADA 2024 guidance) [3].
4. Electronic prescription routes to your chosen Washington pharmacy. Most major chains process e-prescriptions within 2 to 4 hours.
5. If insurance requires prior authorization, the telehealth platform's care coordinator initiates the PA request on the same day. Average PA resolution time in Washington commercial plans is 3, 5 business days [11].
6. First injection training can occur via video or through a local pharmacist under Washington's collaborative pharmacy practice statutes [12].

Telehealth platforms operating in Washington that prescribe insulin include national services such as Teladoc Health, Sesame, and Amazon Clinic, as well as Washington-specific endocrinology telemedicine practices affiliated with the University of Washington Medical Center. Patients should verify that the platform's prescriber holds an active Washington State license before booking.

Labs Required Before Starting Lantus in Washington

Clinicians in Washington order a standard metabolic workup before initiating insulin glargine. No single federal mandate specifies the exact panel, but the ADA 2024 Standards of Care and the American Association of Clinical Endocrinologists (AACE) 2023 consensus both recommend the following baseline tests [3][13]:

• HbA1c: establishes baseline glycemic control and guides initial dose range
• Fasting plasma glucose: confirms fasting hyperglycemia and calibrates titration targets
• Basic metabolic panel (BMP): assesses renal function (eGFR), electrolytes, and hepatic markers that affect insulin clearance
• Thyroid-stimulating hormone (TSH): type 1 patients in particular require thyroid screening given the association with autoimmune thyroid disease [14]
• Urinary albumin-to-creatinine ratio (uACR): screens for diabetic nephropathy, which affects dosing intervals
• Fasting lipid panel: cardiovascular risk stratification per ADA/ACC joint guidelines [15]
• C-peptide and anti-GAD antibodies: optional but commonly ordered when type 1 versus type 2 classification is uncertain

Washington telehealth platforms often provide lab requisitions to LabCorp or Quest Diagnostics locations statewide. Results typically return within 24 to 48 hours for routine panels. A clinician can prescribe Lantus provisionally based on a recent prior HbA1c (within 3 months) if the patient has an established diabetes diagnosis, then adjust dosing once full labs return.

Washington Medicaid (Apple Health) Coverage for Lantus

Washington Apple Health (Medicaid) covers insulin glargine (Lantus) on its preferred drug list for both type 1 and type 2 diabetes, but requires prior authorization in most managed care organization (MCO) contracts [16]. The Health Care Authority's 2024 Preferred Drug List places Lantus in the insulin analogs, long-acting category and specifies that PA criteria include:

1. Documented diagnosis of type 1 or type 2 diabetes with an HbA1c above 7.0% or documented recurrent hypoglycemia on NPH insulin
2. Prescriber attestation that the patient cannot achieve glycemic targets on intermediate-acting insulin (NPH) or documentation of nocturnal hypoglycemia risk
3. Prior NPH insulin trial of at least 30 days OR documented clinical reason for bypassing NPH (e.g., confirmed hypoglycemia unawareness) [16]

Washington Apple Health MCOs include Molina Healthcare of Washington, Community Health Plan of Washington, Coordinated Care, and UnitedHealthcare Community Plan. Each MCO follows the HCA preferred drug list but may have minor variations in the PA submission portal. Prescribers submit PA requests through the relevant MCO's provider portal or via fax, and Washington state law requires MCOs to respond to non-urgent PA requests within 72 hours [17].

Commercially insured Washington patients face variable formulary placement. Most large commercial plans (Premera Blue Cross, Regence BlueShield, Kaiser Permanente Washington) cover Lantus at tier 2 or tier 3 with copays ranging from $35 to $150 per vial without assistance programs.

Commercial Pharmacy Access for Lantus in Washington

Washington pharmacies that regularly stock Lantus vials (10 mL, 100 units/mL) and Lantus SoloStar pens (3 mL, 100 units/mL) include every major chain: Walgreens, CVS, Rite Aid (operating stores), Safeway Pharmacy, Costco Pharmacy, and Fred Meyer Pharmacy. Independent pharmacies throughout the state can order Lantus through McKesson or Cardinal Health with 24-hour turnaround for in-stock items at the regional distribution center.

Cash price for a 10 mL Lantus vial at Washington pharmacies ranges from approximately $280 to $320 without insurance or coupons as of mid-2025. GoodRx and RxSaver coupons commonly bring that price to $115 to $165 at participating locations. Sanofi's Insulins Valyou Savings Program caps out-of-pocket costs at $99 per month for eligible commercially insured patients and offers a $99 per 30-day supply option for uninsured patients [18].

The biosimilar insulin glargine-yfgn (Semglee, Viatris) carries FDA interchangeable status with Lantus as of July 2021, meaning Washington pharmacists may substitute Semglee for Lantus without prescriber authorization unless the prescriber writes "dispense as written" [19]. Semglee cash price typically runs 65 to 70% below branded Lantus, representing a meaningful cost reduction for uninsured patients.

503A Compounding Pharmacies and Insulin Glargine in Washington

Licensed 503A compounding pharmacies in Washington State can prepare patient-specific insulin glargine formulations when a licensed prescriber provides a valid prescription indicating a clinical reason for compounding (e.g., concentration adjustment, preservative sensitivity, or a combination formulation not commercially available) [20].

Washington's Pharmacy Quality Assurance Commission (PQAC) licenses 503A compounders under WAC 246-878. These pharmacies must comply with USP Chapter 797 sterile compounding standards for any injectable preparation, including insulin [21]. The FDA does not list insulin glargine on its 503B outsourcing facility bulk drug list, so compounded insulin glargine from a 503B outsourcing facility for office use is not currently permitted; only patient-specific 503A compounding with an individual prescription is allowed [22].

Patients should request the pharmacy's current PQAC license number and confirm USP 797 compliance before accepting compounded insulin. The Washington PQAC license verification tool is available at doh.wa.gov.

Transferring an Existing Lantus Prescription to Washington

Patients relocating to Washington from another state can transfer an existing Lantus prescription to any Washington pharmacy, subject to the following conditions:

• The original prescription must not be expired (most states issue insulin prescriptions with one-year validity and up to 12 months of refills).
• The transferring pharmacy must be licensed in its original state and able to electronically transmit or verbally communicate the prescription details to the receiving Washington pharmacy.
• Washington law (RCW 69.41) treats insulin as a non-controlled legend drug, so no DEA transfer restrictions apply [23].

If the original prescription has zero refills remaining or has expired, the patient needs a new prescription from a Washington-licensed provider. A telehealth visit typically resolves this within the same business day. Patients should bring glucose logs, prior prescription bottles, and insurance information to expedite the renewal appointment.

Washington pharmacies cannot fill out-of-state controlled-substance prescriptions for Schedule II-V drugs, but since insulin is not scheduled, transfer is straightforward. Patients with concurrent controlled-substance prescriptions (e.g., benzodiazepines for comorbid anxiety) will need separate arrangements for those medications.

Titrating Lantus After the First Prescription

Starting dose is not a permanent dose. The ADA 2024 Standards of Care recommend a "treat-to-target" titration approach for basal insulin, aiming for a fasting glucose of 80 to 130 mg/dL [3]. The validated INSIGHT titration algorithm, used in the EDITION clinical program, instructed patients to increase the basal insulin dose by 2 units every 3 days if fasting glucose remained above 130 mg/dL, and to decrease by 2 units if any fasting glucose reading fell below 80 mg/dL [24].

Washington telehealth providers typically conduct a two-week follow-up visit to review glucose logs and adjust dosing. Patients using continuous glucose monitors (CGM) such as the Dexterity G7 or Libre 3 can share data remotely, allowing clinicians to optimize titration without requiring an in-office visit. The time-in-range target endorsed by the Advanced Technologies and Treatments for Diabetes (ATTD) consensus is greater than 70% of readings between 70 and 180 mg/dL for most adults [25].

Hypoglycemia is the primary dose-limiting adverse event. The ORIGIN trial documented a rate of 1.00 severe hypoglycemia event per 100 patient-years in the glargine arm versus 0.31 per 100 patient-years in the standard care arm over 6.2 years [5]. Patients should receive written hypoglycemia rescue instructions, including glucagon kit or nasal glucagon (Baqsimi) prescribing, at the time of Lantus initiation.

Lantus Storage and Administration for Washington Patients

Unopened Lantus vials and pens must be refrigerated at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius) and discarded by the expiration date on the label [2]. Once opened, a Lantus vial stored at room temperature (below 86 degrees Fahrenheit) remains usable for 28 days. An opened SoloStar pen stored at room temperature is usable for 28 days and should never be refrigerated after first use, as refrigerating an in-use pen may cause dosing inconsistencies.

Washington summers, particularly east of the Cascades, routinely produce ambient temperatures above 86 degrees Fahrenheit. Patients in Spokane, Yakima, or the Tri-Cities region should use insulated medication cases (FRIO or similar) during outdoor activities to prevent heat degradation of their in-use insulin.

Injection sites include the abdomen (preferred for most consistent absorption), outer thigh, upper arm, and buttock. Rotating injection sites within the same region prevents lipohypertrophy, which slows insulin absorption and contributes to erratic glucose control [26].

Cost Assistance Programs Available to Washington Patients

Washington patients have several financial assistance options beyond standard insurance:

Sanofi Insulins Valyou Savings Program: Eligible commercially insured patients pay $99/month. Uninsured patients may qualify for $99 per 30-day supply. Enrollment at insulins.sanofi.us [18].

Washington State Prescription Drug Program: The HCA administers a purchasing pool for uninsured and underinsured state residents. Enrollment does not require income verification for the drug discount program [27].

Patient Assistance Program (PAP): Sanofi provides free Lantus to qualifying uninsured or underinsured patients with household income at or below 400% of the federal poverty level. Applications processed through NeedyMeds or directly via Sanofi's patient services line [28].

340B Program: Washington federally qualified health centers (FQHCs) and rural health clinics participating in the 340B Drug Pricing Program can dispense Lantus at 340B-discounted prices to eligible low-income patients. A list of Washington 340B covered entities is available through HRSA's database [29].

Extra Help (Low Income Subsidy): Medicare Part D beneficiaries in Washington who qualify for Extra Help pay no more than $11.20 per insulin prescription per month under the Inflation Reduction Act $35 insulin copay cap, which applies to all Medicare Part D-covered insulins [30].